Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding
Others
Ratios

Applied Therapeutics (APLT) EBT (2023 - 2025)

Historic EBT for Applied Therapeutics (APLT) over the last 3 years, with Q3 2025 value amounting to -$16.6 million.

  • Applied Therapeutics' EBT rose 4147.11% to -$16.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$96.3 million, marking a year-over-year decrease of 777.86%. This contributed to the annual value of -$100.8 million for FY2024, which is 5953.17% down from last year.
  • According to the latest figures from Q3 2025, Applied Therapeutics' EBT is -$16.6 million, which was up 4147.11% from -$22.7 million recorded in Q2 2025.
  • Applied Therapeutics' EBT's 5-year high stood at -$10.6 million during Q1 2023, with a 5-year trough of -$32.1 million in Q4 2024.
  • Its 3-year average for EBT is -$20.7 million, with a median of -$20.5 million in 2024.
  • Per our database at Business Quant, Applied Therapeutics' EBT plummeted by 9278.93% in 2024 and then soared by 4147.11% in 2025.
  • Over the past 3 years, Applied Therapeutics' EBT (Quarter) stood at -$20.7 million in 2023, then plummeted by 55.21% to -$32.1 million in 2024, then soared by 48.18% to -$16.6 million in 2025.
  • Its EBT stands at -$16.6 million for Q3 2025, versus -$22.7 million for Q2 2025 and -$24.9 million for Q1 2025.